CRVO
No price yet
Announcements
Nothing here yet
Daily updates
- CervoMed reported preliminary Phase 2a biomarker findings for neflamapimod in nonfluent variant primary progressive aphasia, showing a mean reduction in plasma neurofilament light (NfL) over 12 weeks, with larger decreases in patients with higher baseline NfL and no notable safety concerns.Oct 12, 2026
- CervoMed reported favorable Phase 1 pharmacokinetic results for an improved 50 mg neflamapimod tablet, prompting the FDA to remove the prior exposure cap and allow evaluation of higher doses in dementia with Lewy bodies.Sep 28, 2026
FDA designations
Nothing here yet
News
- CervoMed presents initial Phase 2a results for neflamapimod in nonfluent variant primary progressive aphasia, showing positive effects on a key neurodegeneration biomarkerOct 12, 2026
- CervoMed reports pharmacokinetic results for its new oral neflamapimod tablet formulation and secures FDA removal of the drug exposure limitSep 28, 2026
- CervoMed's neflamapimod received UK Innovation Passport designation under the ILAP program for dementia with Lewy bodiesAug 4, 2026
- CervoMed completed enrollment in the Phase 2 study of neflamapimod for primary progressive aphasiaJul 9, 2026
- CervoMed secured a new U.S. patent protecting the use of neflamapimod in pure dementia with Lewy bodies through 2042Jun 18, 2026